Research programme: HBV cccDNA epigenetic modifiers - Arbutus Biopharma

Drug Profile

Research programme: HBV cccDNA epigenetic modifiers - Arbutus Biopharma

Alternative Names: cccDNA epigenetic modifiers - Arbutus Biopharma; Covalently closed circular DNA epigenetic modifiers - Arbutus Biopharma

Latest Information Update: 06 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baruch S. Blumberg Institute; Drexel University College of Medicine
  • Developer Arbutus Biopharma; Baruch S. Blumberg Institute
  • Class Antivirals; Small molecules
  • Mechanism of Action Genetic transcription modulators; Hepatitis B virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Hepatitis B

Most Recent Events

  • 30 Aug 2016 Arbutus terminates its licence for VLP technology with Kuros
  • 03 Aug 2015 Tekmira Pharmaceuticals is now called Arbutus Biopharma
  • 11 Jan 2015 OnCore Biopharma has merged with Tekmira Pharmaceuticals Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top